Content area

|
|

HER2-positiv metastatisk brystkræft

Forfatter(e)

Alan Celik1, Tobias Berg1, 2, Ann Søegaard Knoop2 & Michael Andersson2

1) Danish Breast Cancer Group (DBCG), Københavns Universitetshospital – Rigshospitalet, 2) Onkologisk Klinik, Københavns Universitetshospital – Rigshospitalet

Ugeskr Læger 2021;183:V12200938

Reference: 
Ugeskr Læger 2021;183:V12200938
Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly

Alan Celik, Tobias Berg, Ann Søegaard Knoop & Michael Andersson

Ugeskr Læger 2021;183:V12200938

Breast cancer is the most common type of cancer among women in Denmark. In 15% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on the tumour cells, amplification of the HER2-gene or both are present. HER2-positive mBC is associated with poor disease prognosis. The discovery of HER2 led to the development of HER2-targeting monoclonal antibodies significantly improving survival for patients with HER2-positive mBC as summarised in this review. The future brings even more HER2-targeting drugs, which further can contribute to the palliative treatment of HER2-postive mBC patients.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Kamaran Shorsh | 24/09
2 kommentarer
af Julius Vindbjerg Nissen | 24/09
4 kommentarer
af Carsten Anker Edmund | 24/09
26 kommentarer
af Helle Lone Jensen | 23/09
1 Kommentar
af Martin Gottliebsen | 21/09
2 kommentarer
af Bente Ulla Rasmusson | 20/09
1 Kommentar
af Carsten Reidies Bjarkam | 18/09
1 Kommentar